T2 Biosystems, Inc. (NASDAQ:TTOO – Get Free Report) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $31.05 and traded as low as $3.79. T2 Biosystems shares last traded at $3.95, with a volume of 204,496 shares changing hands.
Analyst Upgrades and Downgrades
Separately, StockNews.com assumed coverage on T2 Biosystems in a research report on Sunday, October 22nd. They issued a “sell” rating on the stock.
T2 Biosystems Price Performance
Insiders Place Their Bets
In other T2 Biosystems news, major shareholder Group L.P. Cr sold 104,014 shares of the company’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of $37.00, for a total value of $3,848,518.00. Following the sale, the insider now owns 30,349 shares in the company, valued at approximately $1,122,913. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 229,708 shares of company stock worth $6,948,906. Corporate insiders own 0.10% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. State Street Corp raised its stake in shares of T2 Biosystems by 11.4% during the 1st quarter. State Street Corp now owns 646,500 shares of the medical equipment provider’s stock worth $339,000 after buying an additional 66,052 shares during the period. Patriot Financial Group Insurance Agency LLC acquired a new position in shares of T2 Biosystems during the 3rd quarter worth approximately $28,000. Banco Santander S.A. acquired a new position in shares of T2 Biosystems during the 3rd quarter worth approximately $42,000. Tudor Investment Corp Et Al acquired a new position in shares of T2 Biosystems during the 3rd quarter worth approximately $42,000. Finally, Jane Street Group LLC acquired a new position in shares of T2 Biosystems during the 3rd quarter worth approximately $28,000. 3.74% of the stock is owned by institutional investors and hedge funds.
About T2 Biosystems
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
- Five stocks we like better than T2 Biosystems
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- The most upgraded stocks in November have two things in common
- ETF Screener: Uses and Step-by-Step Guide
- Monday.com rocked earnings like it’s the weekend
- How to Invest in Casino Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.